Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma
Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma
复制标题
七名 T 细胞淋巴瘤患者的单克隆抗体治疗试验
DOI：
--
复制
发表时间：
1983
期刊：
影响因子：
--
通讯作者：
R. Levy
中科院分区：
文献类型：
--
作者：
Richard A. Miller;A. Oseroff;P. Stratte;R. Levy
我们研究了一种鼠源性抗人T细胞单抗对7例T细胞淋巴瘤患者的临床疗效。每名患者接受4-17次抗Leu-1治疗，疗程为14-75天。抗体剂量从250微克到100毫克不等。抗体治疗通常会导致循环T细胞迅速下降，并在24-48小时内恢复到基线水平。每个患者的最佳剂量似乎各不相同。循环中肿瘤细胞的清除与与细胞结合的抗体的量有关。除1例患者呼吸困难外，未发现严重毒性反应。5例患者有明确的肿瘤反应，但持续时间较短(1.5~4mo)。四名患者产生了抗鼠免疫球蛋白(Ig)抗体，在三名患者中，这是导致肿瘤逃脱治疗的原因。尽管95%的宿主抗小鼠Ig反应是针对小鼠Ig恒定区决定簇的，但仍有一小部分但重要的成分是抗独特型。
We have studied the clinical effects of a murine monoclonal anti-human T-cell antibody in seven patients with T-cell lymphoma. Four to 17 treatments with anti-Leu-1 were given to each patient over periods of 14–75 days. Doses of antibody ranged from 250 micrograms to 100 mg. Antibody treatments usually caused a rapid fall in circulating T cells, with return to baseline levels within 24–48 hr. The optimum dose appeared to vary for each patient. Clearance of circulating tumor cells correlated with the amount of antibody bound to cells. Other than dyspnea in one patient, no serious toxicity was noted. Five patients had definite tumor responses, but these were of short duration (1.5–4 mo). Four patients developed anti-mouse immunoglobulin (Ig) antibodies, and in three patients, this was responsible for tumor escape from therapy. Although 95% of the host anti-mouse Ig response was directed against mouse Ig constant region determinants, a small but significant component was found to be antiidiotype.
DOI：
10.1073/pnas.79.15.4761
发表时间：
1982-01-01
期刊：
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES
影响因子：
--
作者：
HERLYN, D;KOPROWSKI, H
通讯作者：
KOPROWSKI, H
研究单克隆抗体识别的人类 T 淋巴细胞抗原。
DOI：
10.1073/pnas.78.3.1791
发表时间：
1981
影响因子：
11.1
作者：
Engleman,EG;Warnke,R;Fox,RI;Dilley,J;Benike,CJ;Levy,R
通讯作者：
Levy,R
影响因子：
5
作者：
Harmsen, M. M.;van Solt, C. B.;van Zijderveld, F. G.
通讯作者：
van Zijderveld, F. G.